论文部分内容阅读
目的探讨来氟米特治疗难治性原发性肾病综合征的临床疗效。方法研究对象选取2014年11月至2015年11月110例难治性原发性肾病综合征患者,随机分为对照组(采用吗替麦考酚酯与泼尼松联合治疗,55例)和观察组(采用来氟米特与泼尼松联合治疗,55例),检测血白蛋白(Alb)、24 h尿蛋白定量(Up)、总胆固醇(TC)、三酰甘油(TG)、尿素氮(BUN)、血肌酐(Scr)等指标的变化并比较两组的临床效果。结果观察组患者Alb水平明显高于对照组患者,而Up、TC、TG水平明显低于对照组患者,观察组患者总有效率(94.55%)明显高于对照组(69.09%),差异有统计学意义(P<0.05)。结论来氟米特治疗难治性原发性肾病综合征起效快,疗效显著,安全性好,值得临床大力推广使用。
Objective To investigate the clinical efficacy of leflunomide in the treatment of refractory primary nephrotic syndrome. Methods Subjects 110 patients with refractory primary nephrotic syndrome from November 2014 to November 2015 were randomly divided into control group (treated with mycophenolate mofetil and prednisone, 55 cases) and The observation group was treated with leflunomide and prednisone (55 cases). The serum levels of Alb, 24 hours urine protein (Up), total cholesterol (TC), triglyceride (TG), urea Nitrogen (BUN), serum creatinine (Scr) and other indicators of change and to compare the clinical effect of the two groups. Results The Alb level in the observation group was significantly higher than that in the control group, while the levels of Up, TC and TG in the observation group were significantly lower than those in the control group. The total effective rate (94.55%) in the observation group was significantly higher than that in the control group (69.09%) Significance (P <0.05). Conclusion Leflunomide treatment of refractory idiopathic nephrotic syndrome with rapid onset, significant effect, good safety, it is worth promoting the use of clinical.